Johnson & Johnson is a prominent player in the healthcare industry, having strategically refocused on its Innovate Medicine and MedTech segments after separating its Consumer Health business into Kenvue Inc. This strategic pivot aims to capitalize on higher-growth areas with an innovation-driven approach. Investors may find JNJ interesting due to its longstanding commitment to human health and its robust array of advanced medical solutions.
Johnson & Johnson has received strong fundamental scores, reflecting its solid financial health and operations. Below are the detailed ratings in key categories:
| Category | Score | Visualization |
|---|---|---|
| Discounted Cash Flow | 4 | |
| Return On Equity | 5 | |
| Return On Assets | 5 | |
| Debt To Equity | 2 | |
| Price To Earnings | 2 | |
| Price To Book | 1 |
The historical ratings illustrate a consistent performance with slight adjustments over time.
| Date | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2026-03-10 | 3 | 4 | 5 | 5 | 2 | 2 | 1 |
| Previous | 0 | 4 | 5 | 5 | 2 | 2 | 1 |
Analyst estimates indicate a healthy outlook with varied price targets.
| Price Target | Value |
|---|---|
| High | 265 |
| Low | 190 |
| Median | 220 |
| Consensus | 229.33 |
The current analyst sentiment shows a positive tilt towards buying the stock.
| Recommendation | Count | Visualization |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 20 | |
| Hold | 16 | |
| Sell | 3 | |
| Strong Sell | 0 |
Johnson & Johnson remains a robust investment option, with solid fundamentals and a positive outlook from analysts. The company's focused strategy on innovative healthcare solutions positions it well for future growth. However, potential investors should be mindful of sector and company-specific risks that may impact performance. The historical performance indicates consistency, and the current analyst sentiment suggests a generally favorable view on future stock performance.